Cormorant Asset Management’s MBX Biosciences MBX Stock Holding History

Cormorant Asset Management’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.4M	Sell	550,000 -570,000	-51%	-$19.9M	1.56%	20
2026 Q1	$33.4M	Hold	1,120,000	–	–	1.68%	17
2025 Q4	$35.3M	Sell	1,120,000 -105,000	-9%	-$2.55M	1.63%	17
2025 Q3	$21.4M	Buy	1,225,000 +525,000	+75%	+$7.02M	1.48%	18
2025 Q2	$7.99M	Hold	700,000	–	–	0.59%	31
2025 Q1	$5.17M	Hold	700,000	–	–	0.39%	37
2024 Q4	$12.9M	Hold	700,000	–	–	0.71%	33
2024 Q3	$18.2M	Buy	+700,000	New	+$16M	0.96%	32

Other funds holding MBX

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Cormorant Asset Management's MBX Position: Q2 2026 in Review

Cormorant Asset Management reduced its MBX Biosciences (MBX) stake by 51% in Q2 2026, selling an estimated $19.9M and leaving 550,000 shares worth $30.4M. The position accounts for 1.56% of the portfolio, ranked #20.

Cormorant Asset Management first reported a position in MBX in Q3 2024 and has held it in 8 quarters since. The position peaked at $35.3M in Q4 2025. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

Cormorant Asset Management held 550,000 shares of MBX Biosciences worth $30.4M as of Q2 2026.
Cormorant Asset Management sold 570,000 MBX Biosciences shares in Q2 2026, an estimated $19.9M.
MBX Biosciences made up 1.56% of Cormorant Asset Management's portfolio in Q2 2026, its #20 holding.
Cormorant Asset Management first reported a position in MBX Biosciences in Q3 2024 and has held it in 8 quarters since.
Cormorant Asset Management's MBX Biosciences position peaked at $35.3M in Q4 2025.
172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.